The Politics of Personalised Medicine: Pharmacogenetics in the Clinic
暂无分享,去创建一个
[1] Allen D. Roses,et al. Genome-based pharmacogenetics and the pharmaceutical industry , 2002, Nature Reviews Drug Discovery.
[2] M. Pirmohamed,et al. Adverse drug reactions: back to the future. , 2003, British journal of clinical pharmacology.
[3] S. Epstein. Impure Science: AIDS, Activism, and the Politics of Knowledge , 1998 .
[4] E. Oren,et al. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. , 2001, JAMA.
[5] Paul Martin,et al. Genes as drugs: the social shaping of gene therapy and the reconstruction of genetic disease , 1999 .
[6] J. Cummings. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. , 2003, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[7] A. Roses. Genetic testing for Alzheimer disease. Practical and ethical issues. , 1997, Archives of neurology.
[8] Laszlo T Vaszar,et al. Privacy issues in personalized medicine. , 2003, Pharmacogenomics.
[9] W. Evans,et al. Pharmacogenomics: unlocking the human genome for better drug therapy. , 2001, Annual review of pharmacology and toxicology.
[10] K. Lindpaintner. Pharmacogenetics: A New – or not so New?—Concept in Healthcare , 2003 .
[11] H. Brown. Does hope match the hype for targeted drugs? , 2003, The Lancet. Oncology.
[12] M. Rodwin,et al. The Politics of Evidence-Based Medicine , 2001, Journal of health politics, policy and law.
[13] D. Roden,et al. The genetic basis of variability in drug responses , 2002, Nature Reviews Drug Discovery.
[14] J. Speyer. Cardiac dysfunction in the trastuzumab clinical experience. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] A. Relman,et al. America's other drug problem: how the drug industry distorts medicine and politics. , 2002, New republic.
[16] M. Piccart,et al. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] S. Newman,et al. Genetic Screening for Alzheimer's Disease: What Factors Predict Intentions to Take a Test? , 2001, Behavioral medicine.
[18] P. Rioux. Clinical trials in pharmacogenetics and pharmacogenomics: methods and applications. , 2000, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[19] E. Copson,et al. Herceptin (trastuzamab) in advanced breast cancer. , 2000, Cancer treatment reviews.
[20] J. Poirier,et al. Apolipoprotein E Genotype and Gender Influence Response to Tacrine Therapy a , 1996, Annals of the New York Academy of Sciences.
[21] P. Ma,et al. Oncology's trials , 2003, Nature Reviews Drug Discovery.
[22] L. Tan,et al. Her-2/neu and breast cancer. , 2001, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[23] S. Lauri,et al. Cancer patients' decision-making regarding treatment and nursing care. , 2003, Journal of advanced nursing.
[24] S. Harrison. THE POLITICS OF EVIDENCE-BASED MEDICINE IN THE UNITED KINGDOM , 1998 .
[25] J. Murray,et al. Monoclonal antibody therapy for solid tumors. , 2000, Cancer treatment reviews.
[26] S. Perry,et al. The NIH Consensus Development Program , 1987 .
[27] S. Reis,et al. Trastuzumab in the treatment of metastatic breast cancer : anticancer therapy versus cardiotoxicity. , 2000, Circulation.
[28] C. Moyses. Pharmacogenetics, genomics, proteomics : the new frontiers in drug development , 1999 .
[29] Janice M. Reichert,et al. Monoclonal antibodies in the clinic , 2001, Nature Biotechnology.
[30] Robert Wachbroit,et al. 0The Question Not Asked: The Challenge of Pleiotropic Genetic Tests , 1998, Kennedy Institute of Ethics journal.
[31] A. Roses,et al. Pharmacogenetics and future drug development and delivery , 2000, The Lancet.
[32] Amalia M. Issa,et al. Ethical perspectives on pharmacogenomic profiling in the drug development process , 2002, Nature Reviews Drug Discovery.
[33] Maureen Hogan Casamayou. The Politics of Breast Cancer , 2001 .
[34] Venter Jc. Genomic impact on pharmaceutical development. , 2000 .
[35] A. Hedgecoe,et al. Terminology and the Construction of Scientific Disciplines: The Case of Pharmacogenomics , 2003 .
[36] A. E. Ferentz. Integrating pharmacogenomics into drug development. , 2002, Pharmacogenomics.
[37] J. Trojanowski. Tauists, Baptists, Syners, Apostates, and new data , 2002, Annals of neurology.
[38] J. Kahn,et al. Pharmacogenetic challenges for the health care system. , 2002, Health affairs.
[39] M. Gantley,et al. Tensions between policy makers and general practitioners in implementing new genetics: grounded theory interview study , 1999, BMJ.
[40] A D Roses,et al. Apolipoprotein E alleles as risk factors in Alzheimer's disease. , 1996, Annual review of medicine.
[41] L. Fernández-Novoa,et al. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. , 1999, Methods and findings in experimental and clinical pharmacology.
[42] L. Degner,et al. Relationship between preferences for decisional control and illness information among women with breast cancer: a quantitative and qualitative analysis. , 1994, Social science & medicine.
[43] A. Kling,et al. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. , 1986, The New England journal of medicine.
[44] Iona Heath,et al. Managing Scarcity: Priority Setting and Rationing in the National Health Service , 1997 .
[45] B. Latour. The pasteurization of France , 1988 .
[46] M. Luca,et al. ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease: evidence from a peripheral model , 2002, European Neuropsychopharmacology.
[47] V. Jelic,et al. Responder Characteristics to a Single Oral Dose of Cholinesterase Inhibitor: A Double-Blind Placebo-Controlled Study withTacrine in Alzheimer P atients , 2000, Dementia and Geriatric Cognitive Disorders.
[48] J. Potter,et al. Pharmacogenetic screening and therapeutic drugs. , 2002, Clinica chimica acta; international journal of clinical chemistry.
[49] B. Salter. The Politics of Change in the Health Service , 1998 .
[50] Mark A. Rothstein,et al. Ethical and legal implications of pharmacogenomics , 2001, Nature Reviews Genetics.
[51] T. Raffin,et al. Genetic testing and Alzheimer disease: Has the time come? , 1998, Nature Medicine.
[52] J. Hurst. The impact of health economics on health policy in England, and the impact of health policy on health economics, 1972-1997. , 1998, Health economics.
[53] T. Beauchamp,et al. Principles of biomedical ethics , 1991 .
[54] R. Ashcroft. Equipoise, knowledge and ethics in clinical research and practice. , 1999, Bioethics.
[55] F. Boller,et al. The apolipoprotein E ε4 allele and the response to tacrine therapy in Alzheimer’s disease , 2000, European journal of neurology.
[56] D. Nebert. Pharmacogenetics: 65 candles on the cake , 1997 .
[57] P. Watkins,et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. , 1994, JAMA.
[58] R. Frank,et al. New estimates of drug development costs. , 2003, Journal of health economics.
[59] F. W. Robertson,et al. Polymorphism at the Apoprotein‐E locus in relation to risk of coronary disease , 1984, Clinical genetics.
[60] M. Anglin. Working from the inside out: implications of breast cancer activism for biomedical policies and practices. , 1997, Social science & medicine.
[61] I. Ellis,et al. HER-2 in breast cancer--methods of detection, clinical significance and future prospects for treatment. , 2002, Critical reviews in oncology/hematology.
[62] P. Workman. Overview: changing times: developing cancer drugs in genomeland. , 2001, Current opinion in investigational drugs.
[63] A. Roses,et al. Apolipoprotein E Genotype: Utility in Clinical Practice in Alzheimer's Disease , 1996, Journal of the American Geriatrics Society.
[64] G. Siest,et al. Apolipoprotein E Polymorphisms and Concentration in Chronic Diseases and Drug Responses , 2000, Clinical chemistry and laboratory medicine.
[65] G. Ginsburg,et al. Personalized medicine: revolutionizing drug discovery and patient care. , 2001, Trends in biotechnology.
[66] J. Poirier,et al. Apolipoprotein E4, cholinergic integrity and the pharmacogenetics of Alzheimer's disease. , 1998, Journal of neural transmission. Supplementum.
[67] S. Gauthier,et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[68] M S Wilkes,et al. Advertisement-induced prescription drug requests: patients' anticipated reactions to a physician who refuses. , 1999, The Journal of family practice.
[69] R. Bazell. Her-2: the making of herceptin, a revolutionary treatment for breast cancer , 1998 .
[70] P. Trueman,et al. ‘Fourth hurdle reviews’, NICE, and database applications , 2001, Pharmacoepidemiology and drug safety.
[71] J. Law. TECHNOLOGY AND HETEROGENEOUS ENGINEERING: THE CASE OF PORTUGUESE EXPANSION , 2018, SCIENCE & TECHNOLOGY STUDIES.
[72] R. Zussman. Sociological Perspectives on Medical Ethics and Decision-Making , 1997 .
[73] Howard Waitzkin,et al. The Politics of Medical Encounters: How Patients and Doctors Deal With Social Problems , 1991 .
[74] John D. W. Guice,et al. Designing the future: the culture of new trends in science and technology , 1999 .
[75] O. Corrigan,et al. A risky business: the detection of adverse drug reactions in clinical trials and post-marketing exercises. , 2002, Social science & medicine.
[76] M. Ingelman-Sundberg. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy , 2001, Journal of internal medicine.
[77] J. Leon,et al. Pharmacogenomic testing: the cost factor , 2001, The Pharmacogenomics Journal.
[78] J. Ross,et al. The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy , 1998, The oncologist.
[79] Dirk Deleu,et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. , 2001, Neurology.
[80] J Emery,et al. The challenge of integrating genetic medicine into primary care , 2001, BMJ : British Medical Journal.
[81] G. Oberhuber,et al. Is fluorescence in situ hybridization really superior to HercepTest? , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[82] R M. Norton,et al. Clinical pharmacogenomics: applications in pharmaceutical R&D. , 2001, Drug discovery today.
[83] T. P. Hughes. Networks of power : electrification in Western society, 1880-1930 , 1984 .
[84] J. Kurth. Pharmacogenomics: Future Promise of a Tool for Identifying Patients at Risk , 2000 .
[85] C. Møldrup. Ethical, Social and Legal Implications of Pharmacogenomics: A Critical Review , 2002, Public Health Genomics.
[86] W. Sadee's. Pharmacogenomics. Interview by Clare Thompson. , 1999, BMJ.
[87] A. Roses,et al. Apolipoprotein E genotypes in a neuropathological series from the consortium to establish a registry for Alzheimer's disease , 1997, Annals of neurology.
[88] A D Roses,et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. , 1998, The New England journal of medicine.
[89] S. Kumar. Resisting revolution: generalism and the new genetics , 1999, The Lancet.
[90] M. Boyce-Jacino,et al. A SNPshot: pharmacogenetics and the future of drug therapy. , 2000, Trends in biotechnology.
[91] G. Wilcock,et al. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial , 2000, BMJ : British Medical Journal.
[92] Nicholas Schork,et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment , 1999, Nature Genetics.
[93] M. Press,et al. The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognosis of breast cancer. , 1999, Seminars in oncology.
[94] H. Leufkens,et al. The interface between pharmacoepidemiology and pharmacogenetics. , 2000, European journal of pharmacology.
[95] T. Pang,et al. Genomics and global health , 2002, BMJ : British Medical Journal.
[96] J. Abraham. Science, Politics and the Pharmaceutical Industry: Controversy and Bias in Drug Regulation , 1995 .
[97] N. Herrmann,et al. Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease. , 2003, Journal of psychiatry & neuroscience : JPN.
[98] Susan Leigh Star,et al. Changing Order: Replication and Induction in Scientific Practice by H. M. Collins (review) , 1988, Technology and Culture.
[99] R. Anspach,et al. Deciding Who Lives: Fateful Choices in the Intensive-Care Nursery , 1993 .
[100] Harold Maurice Collins,et al. Tantalus and the Aliens: , 1999 .
[101] J Hutton,et al. A nice challenge for health economics. , 2000, Health economics.
[102] J. Olson,et al. Bathsheba’s Breast: Women, Cancer and History , 2004, Nursing History Review.
[103] D. Rosenstein,et al. Clinical Research and the PhysicianPatient Relationship , 2003, Annals of Internal Medicine.
[104] J. Benbassat,et al. Patients' preferences for participation in clinical decision making: a review of published surveys. , 1998, Behavioral medicine.
[105] Butler Rn. ApoE: new risk factor for Alzheimer's. , 1994 .
[106] P. Joubert,et al. Opportunities and strategies for introducing pharmacogenetics into early drug development. , 2001, Drug discovery today.
[107] Donald MacKenzie. The Certainty Trough , 1998 .
[108] R. Zussman. Intensive Care: Medical Ethics and the Medical Profession , 1992 .
[109] F. Roberts. Talking About Treatment: Recommendations for Breast Cancer Adjuvant Treatment , 1999 .
[110] I. Ellis,et al. Recommendations for HER2 testing in the UK , 2000, Journal of clinical pathology.
[111] A. Marshall,et al. Laying the foundations for personalized medicines , 1997, Nature Biotechnology.
[112] S. Liggett. Pharmacogenetic applications of the Human Genome project , 2001, Nature Medicine.
[113] E. Jazwinska. Exploiting human genetic variation in drug discovery and development. , 2001, Drug discovery today.
[114] E. Ferlie,et al. Calman-Hine reassessed: a survey of cancer network development in England, 1999-2000. , 2002, Journal of evaluation in clinical practice.
[115] R. Weinshilboum. The genomic revolution and medicine. , 2002, Mayo Clinic proceedings.
[116] L. Grimaldi,et al. Pharmacogenomics of neurodegenerative diseases. , 2001, European journal of pharmacology.
[117] E. Einsiedel,et al. Consensus Conferences as Deliberative Democracy , 2000 .
[118] G. Frisoni. Treatment of Alzheimer's disease with acetylcholinesterase inhibitors: bridging the gap between evidence and practice , 2001, Journal of Neurology.
[119] M D Rawlins,et al. The failings of NICE , 2001, BMJ : British Medical Journal.
[120] M. Relling,et al. Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.
[121] Richard Smith,et al. The failings of NICE , 2000, BMJ : British Medical Journal.
[122] R. Bast,et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[123] J Marx. New Alzheimer's theory stirs controversy. , 1993, Science.
[124] W. Kalow. Pharmacogenetics: Past and future , 1990 .
[125] S. Miles,et al. Meta-analysis of tacrine for Alzheimer disease: the influence of industry sponsors. , 1999, JAMA.
[126] S. Lovestone,et al. UK Alzheimer's Disease Genetics Consortium , 1999, International journal of geriatric psychiatry.
[127] C. Bosk. Obtaining Voluntary Consent for Research in Desperately Ill Patients , 2002, Medical care.
[128] Simon Lovestone,et al. Alzheimer's disease – do tauists and baptists finally shake hands? , 2002, Trends in Neurosciences.
[129] D. Nebert,et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism , 1988, Nature.
[130] G. Tsongalis,et al. Pharmacogenomics: will it change the field of medicine? , 2001, Clinica chimica acta; international journal of clinical chemistry.
[131] A. Roses,et al. Pharmacogenetics place in modern medical science and practice. , 2002, Life sciences.
[132] Maren Klawiter. Racing for the Cure, Walking Women, and Toxic Touring: Mapping Cultures of Action within the Bay Area Terrain of Breast Cancer , 1999 .
[133] N. Cutler,et al. Cholinesterase Inhibitors: A Therapeutic Strategy for Alzheimer Disease , 1999, The Annals of pharmacotherapy.
[134] D. Hughes,et al. "Ruling in" and "ruling out": two approaches to the micro-rationing of health care. , 1997, Social science & medicine.
[135] Janice M. Reichert,et al. A guide to drug discovery: Trends in development and approval times for new therapeutics in the United States , 2003, Nature Reviews Drug Discovery.
[136] N. Relkin,et al. The National Institute on Aging/Alzheimer's Association Recommendations on the Application of Apolipoprotein E Genotyping to Alzheimer's Disease a , 1996, Annals of the New York Academy of Sciences.
[137] J. Baselga. Clinical trials of Herceptin(trastuzumab). , 2001, European journal of cancer.
[138] H. Wiseman. Tamoxifen: Molecular Basis of Use in Cancer Treatment and Prevention , 1994 .
[139] Paul S. Appelbaum,et al. Informed Consent: Legal Theory and Clinical Practice , 1987 .
[140] T. Bird. Apolipoprotein E genotyping in the diagnosis of alzheimer's disease: A cautionary view , 1995, Annals of neurology.
[141] V. Jordan,et al. Tamoxifen: a most unlikely pioneering medicine , 2003, Nature Reviews Drug Discovery.
[142] Julie A. Johnson,et al. Molecular diagnostics as a predictive tool: genetics of drug efficacy and toxicity. , 2002, Trends in Molecular Medicine.
[143] G. Sanders,et al. Evaluation of genetic tests: APOE genotyping for the diagnosis of Alzheimer disease. , 1999, Genetic testing.
[144] L. Fernández-Novoa,et al. Pharmacological treatment of Alzheimer disease: from psychotropic drugs and cholinesterase inhibitors to pharmacogenomics. , 2000, Drugs of today.
[145] J. Growdon. Apolipoprotein E and Alzheimer disease. , 1998, Archives of Neurology.
[146] Harry Greenberg,et al. Principles, organization, and operation of a DNA bank for clinical trials: a Department of Veterans Affairs cooperative study. , 2002, Controlled clinical trials.
[147] Howard L McLeod,et al. Pharmacogenomics--drug disposition, drug targets, and side effects. , 2003, The New England journal of medicine.
[148] C. Wolf,et al. Science, medicine, and the future: Pharmacogenetics. , 2000, BMJ.
[149] M. Piccart,et al. An overview of HER2. , 2001, Seminars in oncology.
[150] K. Lindpaintner. The importance of being modest--reflections on the pharmacogenetics of abacavir. , 2002, Pharmacogenomics.
[151] David Housman,et al. Why pharmacogenomics? Why now? , 1998, Nature Biotechnology.
[152] S. Shak. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. , 1999, Seminars in oncology.
[153] A. Barry. Political Machines: Governing a Technological Society , 2001 .
[154] B. Gomez-Mancilla,et al. Elements of informed consent for pharmacogenetic research; perspective of the pharmacogenetics working group , 2002, The Pharmacogenomics Journal.
[155] M. Fortun. Mediated speculations in the genomics futures markets , 2001 .
[156] U. Meyer. Pharmacogenetics and adverse drug reactions , 2000, The Lancet.
[157] K. Lackner,et al. Pharmacogenomics: implications for laboratory medicine. , 2001, Clinica chimica acta; international journal of clinical chemistry.
[158] John A. Robertson,et al. Consent and privacy in pharmacogenetic testing , 2001, Nature Genetics.
[159] P. Amouyel,et al. APOE genotyping and response to drug treatment in Alzheimer's disease , 1997, The Lancet.
[160] Alberto Cambrosio,et al. Exquisite Specificity: The Monoclonal Antibody Revolution , 1995 .
[161] J. Poirier. Apolipoprotein E: a pharmacogenetic target for the treatment of Alzheimer's disease. , 1999, Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology.
[162] S. Frantz,et al. New drug approvals for 2002 , 2003, Nature Reviews Drug Discovery.
[163] J. Poirier,et al. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease , 1998, Neurology.
[164] G. Banna,et al. BRCA-1 and BRCA-2 mutations as prognostic factors in clinical practice and genetic counselling. , 2001, Cancer treatment reviews.
[165] F. Mullan,et al. The town meeting for technology. The maturation of consensus conferences. , 1985, JAMA.
[166] G. Hortobagyi,et al. Integration of trastuzumab into adjuvant systemic therapy of breast cancer: ongoing and planned clinical trials. , 2001, Seminars in oncology.
[167] B. Wynne,et al. Misunderstanding science? : the public reconstruction of science and technology , 1996 .
[168] M. Untch,et al. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[169] R. C. Fox,et al. Medical Morality Is Not Bioethics—Medical Ethics in China and the United States , 2015, Perspectives in biology and medicine.
[170] P. Corey,et al. Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .
[171] Marc Berg,et al. The practice of medical technology. , 2003, Sociology of health & illness.
[172] C. McNeil. Herceptin raises its sights beyond advanced breast cancer. , 1998, Journal of the National Cancer Institute.
[173] D C McCrory,et al. Empirical research on informed consent. An annotated bibliography. , 1999, The Hastings Center report.
[174] C. Caldas,et al. Impact of genomics on drug discovery and clinical medicine. , 2000, QJM : monthly journal of the Association of Physicians.
[175] J. Aerssens. Pharmacogenomic approaches in Alzheimer's disease drug development , 2002 .
[176] M Pirmohamed,et al. Genetic susceptibility to adverse drug reactions. , 2001, Trends in pharmacological sciences.
[177] B. Kakulas,et al. Apolipoprotein E genotyping in the diagnosis of Alzheimer's disease: A cautionary view , 1995, Annals of neurology.
[178] R. Rapp. Testing women, testing the fetus , 1999 .
[179] N. Relkin,et al. Apolipoprotein E genotyping in Alzheimer's disease , 1996, The Lancet.
[180] Reinhart Koselleck,et al. Futures Past: On the Semantics of Historical Time , 1985 .
[181] E. Peskind,et al. Galantamine in AD , 2000, Neurology.
[182] Patricia L. Marshall,et al. The Decision Dynamics of Clinical Research: The Context and Process of Informed Consent , 2002, Medical care.
[183] A D Roses,et al. Apolipoprotein E and Alzheimer's Disease A Rapidly Expanding Field with Medical and Epidemiological Consequences , 1996, Annals of the New York Academy of Sciences.
[184] G. Hortobagyi,et al. Ongoing and planned adjuvant trials with trastuzumab. , 2000, Seminars in Oncology.
[185] Michael Doherty,et al. Pharmacogenetics--legal, ethical and regulatory considerations. , 2001, Pharmacogenomics.
[186] R. Bullock. New drugs for Alzheimer's disease and other dementias , 2002, British Journal of Psychiatry.
[187] R. Macklin. Against Relativism: Cultural Diversity and the Search for Ethical Universals in Medicine , 1999 .
[188] M. H. Ensom,et al. Pharmacogenetics , 2001, Clinical pharmacokinetics.
[189] H. Paulson. Diagnostic testing in neurogenetics. Principles, limitations, and ethical considerations. , 2002, Neurologic clinics.
[190] M Farlow,et al. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. , 1992, JAMA.
[191] S. Schnitt,et al. Current status of HER2 testing: caught between a rock and a hard place. , 2001, American journal of clinical pathology.
[192] S. Lovestone,et al. Consensus Statement on Predictive Testing for Alzheimer Disease , 1995, Alzheimer disease and associated disorders.
[193] Giovanni B. Frisoni,et al. Consensus report of the working group on: 'Molecular and biochemical markers of Alzheimer's disease' , 1998 .
[194] C. Sinding. Literary Genres and the Construction of Knowledge in Biology: Semantic Shifts and Scientific Change , 1996 .
[195] B. Latour. Science in action : how to follow scientists and engineers through society , 1989 .
[196] W. A. Gool. The Use of Apolipoprotein E Genotyping as a Diagnostic Test in Suspected Alzheimer's Disease , 1996 .
[197] Jordan Goodman,et al. The Story of Taxol: Nature and Politics in the Pursuit of an Anti-Cancer Drug , 2001 .
[198] Robertson Js,et al. Anticipating response to predictive genetic testing for Alzheimer's disease: a survey of first-degree relatives. , 2000 .
[199] R. Klein. The politics of the National Health Service , 1983 .
[200] K S Kosik,et al. Public attitudes about genetic testing for Alzheimer's disease. , 2001, Health affairs.
[201] A D Roses,et al. The role of apolipoprotein E in Alzheimer's disease: pharmacogenomic target selection. , 2000, Biochimica et biophysica acta.
[202] C. Freeman. Economics of Industrial Innovation , 1975 .
[203] I. Varekamp,et al. Age rationing for renal transplantation? The role of age in decisions regarding scarce life extending medical resources. , 1998, Social science & medicine.
[204] B. Leyland-Jones. Trastuzumab: hopes and realities. , 2002, The Lancet. Oncology.
[205] K. Taylor,et al. Integrating conflicting professional roles: physician participation in randomized clinical trials. , 1992, Social science & medicine.
[206] K. Lindpaintner. Genetics in drug discovery and development: challenge and promise of individualizing treatment in common complex diseases. , 1999, British medical bulletin.
[207] S. Wiley. Genomics in the real world. , 1998, Current pharmaceutical design.
[208] A. Marshall,et al. Getting the right drug into the right patient , 1997, Nature Biotechnology.
[209] N. Risch,et al. Statement on use of apolipoprotein E testing for Alzheimer disease. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer disease. , 1995, JAMA.
[210] G. Wilcock,et al. Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease , 1998, International journal of geriatric psychiatry.
[211] L. Bracco,et al. Pharmacogenomics and Personalised Medicine , 2002 .
[212] J. Johnson,et al. Pharmacogenomics: the inherited basis for interindividual differences in drug response. , 2001, Annual review of genomics and human genetics.
[213] A Regalado,et al. Inventing the pharmacogenomics business. , 1999, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[214] A. Roses. Apolipoprotein E Affects the Rate of Alzheimer Disease Expression: (β-Amyloid Burden Is a Secondary Consequence Dependent on APOE Genotype and Duration of Disease , 1994, Journal of neuropathology and experimental neurology.
[215] P. Oestreicher. 4th Annual Pharmacogenomics and Medicine Lectures. , 2001, Pharmacogenomics.
[216] Paul Martin,et al. The Drugs Don't Work , 2003, Social studies of science.
[217] N. Greig,et al. Current drug targets for Alzheimer's disease treatment , 2002 .
[218] C. Newdick. Who Should We Treat?: Law, Patients and Resources in the NHS , 1995 .
[219] David H. Guston,et al. Evaluating the First U.S. Consensus Conference: The Impact of the Citizens’ Panel on Telecommunications and the Future of Democracy , 1999 .
[220] A. Roses. Apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer's disease , 1995, Annals of neurology.
[221] R. W. Hansen,et al. The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.
[222] P. Workman. Scoring a bull's-eye against cancer genome targets. , 2001, Current opinion in pharmacology.
[223] S. Lovestone. Genetics consortiums can offer views facilitating best practice in Alzheimer's disease , 1998, BMJ.
[224] R. March. Pharmacogenomics: The Genomics of Drug Response , 2000, Yeast.
[225] A. Gafni,et al. On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales. , 2002, Health economics.
[226] S. Batt. Patient No More, the Politics of Breast Cancer , 1994 .
[227] U. A. Meyers. Molecular genetics and the future of pharmacogenetics , 1990 .
[228] R. Chadwick. Criteria for genetic screening: the impact of pharmaceutical research , 1999 .
[229] A. Roses. Pharmacogenetics and the practice of medicine , 2000, Nature.
[230] N. Dracopoli,et al. Applied genomics: integration of the technology within pharmaceutical research and development. , 2000, Current opinion in biotechnology.
[231] Utilization of new technologies in drug trials and discovery. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[232] M. Hung,et al. Role of erbB2 in breast cancer chemosensitivity. , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.
[233] M. Pericak-Vance,et al. Clinical application of apolipoprotein E genotyping to Alzheimer's disease , 1994, The Lancet.
[234] A. Relman. Tacrine as a Treatment for Alzheimer's Dementia , 1991 .
[235] D. Slamon,et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[236] Mace L. Rothenberg,et al. Improving the evaluation of new cancer treatments: challenges and opportunities , 2003, Nature Reviews Cancer.
[237] Arie Rip,et al. The Rise of Membrane Technology , 1998 .
[238] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[239] K. Fox,et al. Thrombolytic treatment for elderly patients. , 1992, BMJ.
[240] R. Westrum. The Social Construction of Technological Systems , 1989 .
[241] R. Walker. The failings of NICE. "Spinning" is not nice. , 2001, BMJ.
[242] David H. DeVorkin,et al. Inventing Accuracy: A Historical Sociology of Nuclear Missile Guidance , 1990 .
[243] A. Issa,et al. Apolipoprotein E Genotyping for Pharmacogenetic Purposes in Alzheimer's Disease: Emerging Ethical Issues , 2000, Canadian journal of psychiatry. Revue canadienne de psychiatrie.
[244] P. Littlejohns,et al. The cancer technology appraisal programme of the UK's National Institute for Clinical Excellence. , 2003, The Lancet. Oncology.
[245] P. Tariot,et al. Oral tetrahydroaminoacridine in the treatment of senile dementia, Alzheimer's type. , 1987, The New England journal of medicine.
[246] A. Roses,et al. Prediction for unimpaired subjects is different from diagnosis of demented patients , 1997, Annals of neurology.
[247] B. Freedman. Equipoise and the ethics of clinical research. , 1987, The New England journal of medicine.
[248] B. Rothman. Genetic Maps and Human Imaginations: The Limits of Science in Understanding Who We Are , 1998 .
[249] A. Roses,et al. The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective. , 1997, JAMA.
[250] M. Pericak-Vance,et al. Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease , 1996, The Lancet.
[251] R. Kisabeth,et al. Pharmacogenomics: a clinician's primer on emerging technologies for improved patient care. , 2001, Mayo Clinic proceedings.
[252] S. DeKosky,et al. Apolipoprotein E genotyping in the diagnosis of alzheimer's disease , 1995 .
[253] H. Sakul,et al. Chapter 23. Pharmacogenomics , 2000 .
[254] R. Woodman. Storage of human organs prompts three inquiries , 2000, BMJ : British Medical Journal.
[255] H. Hoyme,et al. Pharmacogenomics: the future of drug therapy , 2002, Clinical genetics.
[256] Pharmacogenetics: the ethical context , 2001, The Pharmacogenomics Journal.
[257] From the lab to the clinic: integration of pharmacogenics into clinical development. , 2002, Pharmacogenomics.
[258] E. Vesell,et al. Genetic Variation as a Guide to Drug Development , 1998, Science.
[259] K. Blennow,et al. Tacrine and rate of progression in Alzheimer's disease – relation to ApoE allele genotype , 2001, Journal of Neural Transmission.
[260] S. Akhtar. Pharmacogenomics: Are pharmacists ready for genotyped prescribing? , 2002 .
[261] P. Amouyel,et al. Genetic susceptibility factors for Alzheimer's disease. , 2001, European journal of pharmacology.
[262] M Heath-Chiozzi,et al. Clinical application of pharmacogenetics. , 2001, Trends in molecular medicine.
[263] A Whitehead,et al. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration. , 1998, JAMA.
[264] K. Mokbel,et al. From HER2 to Herceptin , 2001, Current medical research and opinion.
[265] J W Jukema,et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. , 1998, The New England journal of medicine.
[266] L. Vaszar,et al. Pharmacogenomics and the challenge to privacy , 2002, The Pharmacogenomics Journal.
[267] S Galloway,et al. Information needs of women during early treatment for breast cancer. , 1997, Journal of advanced nursing.
[268] A. D. Roses,et al. Association of apolipoprotein E allele €4 with late-onset familial and sporadic Alzheimer’s disease , 2006 .
[269] Amalia M. Issa,et al. Ethical considerations in clinical pharmacogenomics research. , 2000, Trends in pharmacological sciences.
[270] Eduardo Bruera,et al. Treatment decisions for breast carcinoma , 2002, Cancer.
[271] S. Post. On Not Jumping the Gun: Ethical Aspects of APOE Gene Testing for Alzheimer's Disease a , 1996, Annals of the New York Academy of Sciences.
[272] T. Pinch,et al. The Social Construction of Facts and Artefacts: or How the Sociology of Science and the Sociology of Technology might Benefit Each Other , 1984 .
[273] M. Bleavins,et al. Pharmacogenetic application in drug development and clinical trials. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[274] Kathleen Jordan,et al. The Dissemination, Standardization and Routinization of a Molecular Biological Technique , 1998 .
[275] L. Furness,et al. Pharmacogenomics - it's not just pharmacogenetics. , 1998, Current opinion in biotechnology.
[276] W. Weber,et al. The legacy of pharmacogenetics and potential applications. , 2001, Mutation research.
[277] W. Haseltine. Not quite pharmacogenomics , 1998, Nature Biotechnology.
[278] D. Miles. Update on HER-2 as a target for cancer therapy: Herceptin in the clinical setting , 2001, Breast cancer research : BCR.
[279] A. Roses. SNPs—where's the beef? , 2002, The Pharmacogenomics Journal.
[280] Ferguson Jh. The NIH Consensus Development Program. The evolution of guidelines. , 1996 .
[281] Greg Myers,et al. Writing biology : texts in the social construction of scientific knowledge , 1990 .
[282] L Lasagna,et al. Cost of innovation in the pharmaceutical industry. , 1991, Journal of health economics.
[283] S. Humphries,et al. Apolipoprotein E genotyping in Alzheimer's disease , 1996, The Lancet.
[284] Simon Joss,et al. Participatory technology assessment: European perspectives , 2002 .
[285] B. Lerner,et al. The Breast Cancer Wars: Hope, Fear, and the Pursuit of a Cure in Twentieth Century America , 2004, Nursing History Review.